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REVIEW
PREVENTION OF PREECLAMPSIA WITH LOW-DOSE
ASPIRIN – A SYSTEMATIC REVIEW AND META-
ANALYSIS OF THE MAIN RANDOMIZED
CONTROLLED TRIALS
Rodrigo Ruano, Rosana S. Fontes, and Marcelo Zugaib
Ruano R, Fontes RS, Zugaib M. Prevention of preeclampsia with low-dose aspirin – a systematic review and meta-analysis
of the main randomized controlled trials. Clinics. 2005;60(5):407-14.
The purpose of this paper is to evaluate the effectiveness of low-dose aspirin in the prevention of preeclampsia in low-risk and
high-risk women. We identified randomized clinical trials of the use of low-dose aspirin to prevent preeclampsia through the
PUBMED search engine, and through the Cochran Library database. Twenty-two studies met our inclusion criteria, and were
divided according to the studied population into 2 groups: trials with women at low risk for preeclampsia and trials with women
at high risk. Effects were measured through the incidence of preeclampsia in women taking either placebo or aspirin, in studies
where the relative risks and the 95% confidence intervals were calculated for both groups. A total of 33,598 women were studied,
comprising 5 trials with 16,700 women at low-risk and 17 trials including 16,898 women at high risk. The incidence of preeclampsia
was 3.75% (626/17,700), in the low-risk group, 9.01% (1,524/16,898) in the high-risk group, and 6.40% (2,150/33,598) overall.
Low-dose aspirin had no statistically significantly effect on the incidence of preeclampsia in the low-risk group (RR = 0.95, 95%
CI = 0.81-1.11), but had a small beneficial effect in the high-risk group (RR = 0.87, 95% CI = 0.79-0.96). Therefore, low-dose
aspirin is mildly beneficial in terms of reducing the incidence of preeclampsia in women at high risk of developing preeclampsia.
KEYWORDS: Preeclampsia. Prevention. Aspirin. Meta-Analysis.
Preeclampsia, defined as hypertension associated with
proteinuria and/or general edema,1 continues to fascinate
clinicians and basic scientists mainly because of its un-
known etiological mechanisms and its complex pathophysi-
ology. In spite of recent advances in prenatal care,
preeclampsia remains a major cause of maternal and peri-
natal morbidity and mortality throughout the world.2 In gen-
eral, preeclampsia complicates 2% to 8% of pregnancies,
and it is still responsible for 10% to 15% of maternal mor-
tality.2,3
The cause of preeclampsia remains unknown, but since
the 1980s, the discovery that disordered arachidonic acid
metabolism may play an important role in its pathogenesis
has encouraged the use of low-dose aspirin to block this
mechanism, and consequently to prevent preeclampsia.4,5
Preeclampsia is associated with a relative deficiency of
intravascular production of prostacyclin (a vasodilator) and
excessive production of thromboxane (a vasoconstricting
prostaglandin synthesized by aggregated platelets).6 The
hypothesis that antiplatelet agents such as low-dose aspi-
rin may prevent preeclampsia has been widely tested in
randomized trials. However, controversial results have been
reported, with a few trials exhibiting compelling results;
however, many of the largest trials to date failed to con-
firm any real benefit of low-dose aspirin in preventing
preeclampsia.7 Additionally, it is not clear whether low-dose
aspirin is beneficial only for women at high risk of devel-
oping preeclampsia, rather than also for women at low risk.
Based on this controversial condition, we reviewed the
English language medical literature (MEDLINE and other
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data at the National Library of Medicine, accessed using
the PUBMED search engine, as well as the Cochrane Li-
brary, searching for prospective studies consisting of
randomized, double-blinded trials that compared the use of
low-dose aspirin versus placebo to prevent preeclampsia,
to evaluate the benefits of this medication in the preven-
tion of preeclampsia either in low-risk or in high-risk
populations.
DATA SOURCES
Studies were identified using several search strategies
such as using available electronic databases and references
of either published articles or chapters from textbooks. The
electronic databases used were MEDLINE and other data
at the National Library of Medicine, accessed using the
PUBMED search engine, as well as the Cochrane Library.
We included only randomized, double-blinded trials (pro-
spective observational studies) comparing the use of low-
dose aspirin to placebo for the prevention of preeclampsia.
Only completely published studies from January 1983 to
December 2003 were included in this systematic review.
Abstracts, unpublished trials, reviews, meta-analyses, ret-
rospective studies, case-control studies, and trials that did
not match our inclusion criteria were excluded. Each trial
was individually analyzed, and included in our study if it
matched our inclusion criteria.
STUDY SELECTION
Two reviewers (R.R. and R.F.) assessed each study in-
dependently. Inclusion criteria for this investigation were
randomized clinical trials that evaluated the effect of low-
dose aspirin on prevention of preeclampsia in comparison
with placebo.
We assessed the validity of each included trial accord-
ing to the criteria outlined in the Cochrane handbook.8 Each
trial received a grade for concealment of allocation, and
studies with unsatisfactory quality were excluded. In all
studies, data were extracted independently from each pub-
lished manuscript by 1 of 2 of us (R.R. and R.F.), and data
were only included and tabulated if the 2 reviewers had in-
dependently achieved the same result. When present, dis-
crepancies were resolved by discussion, and the authors
extracted the data together. However, if agreement between
the authors was not possible, the study was then excluded.
In order to tabulate and integrate the data source, we
had previously established that the studied populations
would be divided into 2 groups: a) women at low risk of
developing preeclampsia, and b) women at high risk for
preeclampsia. Women at high risk of developing
preeclampsia were identified as those who had essential
chronic arterial hypertension prior to the pregnancy, insu-
lin-treated diabetes, or an antecedent of severe preeclampsia
(including eclampsia, HELLP syndrome, blood pressure ³
160/110 mm Hg, imminence of eclampsia, respiratory dis-
tress, or renal failure). In other studies, women at high risk
for preeclampsia were identified by positive tests such as
those for Doppler ultrasonography, the rollover test, or the
angiotensin II sensitivity test. Women at low risk for
preeclampsia were considered to be those without any risk
factor or any of the positive predictive tests described
above. Therefore, we first tried to select and classify each
trial according to the population of interest. If the trial had
mixed both populations, we decided to exclude the trial
from our analysis.
Clinical heterogeneity was evaluated by the gestational
age in which women were included in the study, the dura-
tion of medication and dosage of aspirin used in each trial,
and the definition of high risk for preeclampsia adopted in
each study (i.e. the inclusion criteria that defined being at
high risk of developing preeclampsia).
The main outcome of interest to our analysis was the
incidence of preeclampsia in women who had received low-
dose aspirin in comparison to those who had taken the pla-
cebo, dividing these women into the 2 groups previously
described (at low risk and at high risk of developing
preeclampsia). As the incidence of preeclampsia was the
main outcome of interest, we only included prospective lon-
gitudinal studies, excluding, as previously described, case-
control ones. Although preeclampsia is defined by the on-
set of arterial hypertension (≥ 140/90 mm Hg) after 20 ges-
tational weeks associated with proteinuria and/or general
edema,9,10 to facilitate analysis we considered only those
cases with increasing blood pressure after 20 weeks of ges-
tation associated with proteinuria ≥ 300 mg per 24 hours.
Tabulation of the data sources was performed using Ex-
cel® spreadsheet software (Microsoft®, USA). Two inde-
pendent tables were compiled: one including low-risk, one
including high-risk women. Effect was estimated by cal-
culating the relative risk and the 95% confidence intervals;
a Mantel-Haenszel fixed-effects model was used. Statisti-
cal heterogeneity was assessed using the chi-square test,
and the absence of experimental intervention effect was also
tested (RR = 1).
RESULTS
A total of 22 randomized trials matched our inclusion
criteria. Once integrated into our analysis, a total of 33,598
prospectively studied women were included. Five of these
studies focused on 16,700 women at low risk of develop-
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ing preeclampsia, while 17 trials followed 16,898 women
at high risk (Tables 1 and 2).
Good agreement between reviewers for selection and
assessment of validity was observed, and discrepancies
were easily resolved. Only trials with satisfactory conceal-
ment of allocation were included.
Among the 5 trials that evaluated women at low risk
for preeclampsia (Table 1), 2 studies used 60 mg/day of
aspirin,11,12 1 used 75 mg/day,13 and 2 used 100 mg/day.14,15
Four trials started giving aspirin to women in the first tri-
mester,12-15 and 1 study included women in the second tri-
mester.11 In the first 2 trials,11,12 a significant reduction in
the incidence of preeclampsia was observed among those
women who received aspirin (RR = 0.73 and 95% CI =
0.54-0.99, RR = 0.29 and 95% CI = 0.11-0.79, respec-
tively), but the 3 latter studies did not demonstrate any ben-
efit of low-dose aspirin (Figure 1).
Among the 17 trials that evaluated women at high risk
for preeclampsia (Table 2), the various main inclusion cri-
teria were as follows: previous maternal history (2 stud-
ies)16,17; pregestational maternal disease, previous severe
preeclampsia, or multiple gestation (6 studies)18-23; an ab-
normal Doppler examination (7 studies)24-29,32; positive
rollover test (1 study)30; and a positive angiotensin II sen-
sitivity test (1 study).31 Regarding aspirin dosages given to
high-risk women, the following variations occurred: 50 to
60 mg/day (9 studies)17,19-23,26,27; 75 mg/day (1 study)24; 81
mg/day (1 study)18; 100 mg/day (5 studies)16,,25,28-30; and 150
mg/day (1 study).32
In 11 trials, women started taking aspirin in the second
trimester,16,18,21,24-28,30-32 while in 6 studies women started tak-
ing aspirin in the first trimester.17,19-23,29 In 9 studies, pri-
marily those in the former group, a preventive role of low-
dose aspirin was observed, with a relative risk varying from
Table 2 - Characteristics of randomized trials including women at high risk for preeclampsia
# Study Location of GA at Dose of aspirin Inclusion criteria of high risk
the study inclusion
6 Beaufils et al, 198516 France 16 w 100 mg/day previous history
7 Wallenburg et al, 198631 Netherlans 28 w 60 mg/day angiotensin II sensitive
8 Benigni et al, 198917 Italy 12 w 60 mg/day previous history
9 Schiff et al, 198930 Israel 2 8w 100 mg/day rollover test
10 McParland et al, 199024 UK 24 w 75 mg/day Doppler (PI > 95th centile)
11 Porreco et al, 199318 USA 33 w 81 mg/day multifetal gestations
12 Wiinikka et al, 199319 Finland 12-18 w 50 mg/day pre-existing hypertension or previous severe
preeclampsia
13 CLASP, 199420 USA 12-32 w 60 mg/day clinical condition
14 Wenstrom et al, 199521 USA 22 w 60 mg/day pregestational diabetes, pre-existing hypertension,
multifetal gestations, renal disease
15 ECPPA, 199622 Brazil 12-32 w 60 mg/day pregestational diabetes, preexisting hypertension,
multifetal gestations, previous severe preeclampsia,
renal disease
16 Morris et al, 199625 Australia 18 w 100 mg/day Doppler (S/D > 3.3 or S/D > 3 and notch)
17 Bower et al, 199626 UK 18-22 w 60 mg/day Doppler (PI > 95th centile)
18 Zimmermann et al, 199727 Italy 22-24 w 50 mg/day Doppler (bilateral notch)
19 Caritis et al, 199823 USA 13-26 w 60 mg/day pregestational diabetes, pre-existing hypertension,
multifetal gestations, previous severe preeclampsia
20 Harrington et al, 200028 UK 17-23 w 100 mg/day Doppler (RI > 50% and bilateral notch or RI > 90%
and unilateral notch or RI > 95%)
21 Mére-Enfant (2), 200329 France and Belgium 14 w 100 mg/day Doppler (PI > 95th centile)
22 Yu et al, 200332 Different countries 23 w 150 mg/day Doppler (PI > 95th centile)
#: trial; w: weeks; GA: gestational age.
Table 1 - Characteristics of randomized trials including women at low risk for preeclampsia
# Study Location of the study GA at inclusion Dose of aspirin
1 Hauth et al, 199311 USA 20-22 w 60 mg/day
2 Sibai et al, 199312 USA 13-26 w 60 mg/day
3 Rotchell et al, 199813 UK 12-32 w 75 mg/day
4 Jamaica et al, 199814 Jamaica 12-32 w 100 mg/day
5 Mére-Enfant (1), 200315 France and Belgium 14-20 w 100 mg/day
#: trial; w: weeks; GA: gestation age
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0.06 to 0.7516-18,21,24-26,28,30,31; others showed no considerable
benefits of the low-dose aspirin in preventing
preeclampsia19,20,22,27,23,29,32 (Figure 2).
The overall incidence of preeclampsia was 6.40%
(2,150/33,598). The incidences of preeclampsia in the low-
risk and in the high-risk populations were 3.75% (626/
16,700) and 9.01% (1,524/16,898), respectively.
In women at low risk of developing preeclampsia, 8,352
women received prophylactic low-dose aspirin while 8,348
women took a placebo. Preeclampsia was observed in 305
Figure 1 - Effect of low-dose aspirin in the expected outcome in women at low risk for preeclampsia
Figure 2 - Effect of low-dose aspirin in the expected outcome in women at high risk for preeclampsia
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(3.65%) women who took low-dose aspirin, and in 321
(3.85%) women who took a placebo (RR = 0.95, 95% CI
= 0.81-1.11) (Figure 1).
In women at high risk of developing preeclampsia,
8,679 women took low-dose aspirin while 8,219 took a pla-
cebo. Preeclampsia occurred in 713 (8.22%) women who
received low-dose aspirin, and in 811 (9.87%) women who
took a placebo (RR = 0.87, 95% CI = 0.79-0.96) (Figure
2).
Although different doses of aspirin were used in each
trial, there was no correlation between dose of aspirin and
prevention of preeclampsia (correlation coefficient r =
0.064, Figure 3).
DISCUSSION
Our systematic review and meta-analysis shows that
low-dose aspirin has a small effect in the prevention of
preeclampsia in women considered to be at high risk for
the disease (RR = 0.87). The analysis confirms the tendency
of recent randomized trials that have been demonstrating
the small effect of low-dose aspirin in the prevention of
preeclampsia.
The validity of this analysis depends on the methodo-
logical strength of our review. We used a prospective proto-
col and attempted to find all the evidence. Only randomized
controlled studies that were completely and clearly described
were included in our meta-analysis, because they are the
most reliable method of assessing efficacy of therapeutic in-
terventions in the incidence of a special disease. To exclude
interpreted data, previous reviews and meta-analyses were
not included. Since an extremely important issue related to
meta-analysis is the quality of studies, we considered only
studies with high quality, which may have reduced the
number of studies analyzed in our review.33
Another important issue in a meta-analysis is the de-
gree of heterogeneity of design of the included studies.
Excessive heterogeneity reduces the validity of the ap-
proach. On the other hand, although absolute design ho-
mogeneity among studies would be ideal and desirable, this
is an almost impossible goal to achieve. However, the prob-
lem can be avoided by understanding and analyzing the
sources of heterogeneity.33
To achieve this, we first, established that our principal
measure of effect would be the incidence of preeclampsia,
defined as a blood pressure increase after 20 weeks of ges-
tation associated with proteinuria ≥ 300 mg per 24 hours.
Gestational hypertension (increasing blood pressure with-
out proteinuria) was not considered to be an indication of
preeclampsia. Additionally, we did not evaluate other out-
comes, such as prematurity, or fetal growth restriction, as
we believe that these may be consequences of
preeclampsia.
Differences in aspirin dosage and duration of treatment
were also observed among studies. Earlier studies tended
to use lower doses of aspirin (50-75 mg/day), while more
recent trials used 100 mg/day aspirin. Wallenburg34 pointed
out that the difference between early and recent trials re-
garding the aspirin dosage have influenced the results. In
his opinion, daily doses of 60 to 80 mg of aspirin effec-
tively inhibit platelet thromboxane synthesis, but these may
not be sufficient to affect placental thromboxane. Never-
theless, in the present review, the more recent trials have
not disclosed any benefit in the prevention of preeclampsia
with the higher dose of aspirin (100-150 mg/day), a fact
confirmed in our analysis by demonstrating that differences
in aspirin dosage did not correlate with the relative risk for
preeclampsia.
Although little attention has been paid in published tri-
als to the timing of aspirin administration (duration of treat-
ment), some studies suggest greater efficacy when aspirin
treatment begins before 17 or 20 weeks,7,20,35,36 while oth-
ers find no benefits with earlier treatment.13,15,23,29,37 In this
study, we observed no obvious correlation between timing
of aspirin administration and prevention of preeclampsia,
although this point could not be definitely evaluated be-
cause the timing of aspirin administration varied between,
and even within a number of trials. The duration of aspi-
rin administration should be carefully evaluated in all fu-
ture clinical trials.
The last and most important cause of clinical hetero-
geneity was the inclusion criteria of high, or low risk of
developing preeclampsia (Tables 1 and 2). As Table 2 dem-
onstrates, different inclusion criteria were used in each trial
to define women at high risk for preeclampsia. Previous
severe preeclampsia, preexisting hypertension,
pregestational diabetes, renal disease, and multifetal
gestations are well known risk factors for preeclampsia.37-39
However, in many studies, all these conditions, which may
have different pathophysiology, are mixed together,. There-
Figure 3 - Correlation between dose of aspirin and relative risk for
preeclampsia in each trial
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fore, it should be of interest to randomize women accord-
ing to each different risk factor in further trials. Addition-
ally, the positive rollover test and the positive angiotensin
II sensitivity test were the inclusion criteria in 2 trials.30,31
In 7 trials, abnormal uterine Doppler indexes were used to
recruit participants.24-29,32 These tests are considered to be
methods of predicting preeclampsia, although their reported
accuracy is variable.40-42 In addition, although nulliparity
is theoretically considered to be a risk factor for
preeclampsia,39 in all but 1 study, 15 nulliparity was not con-
sidered to be a high-risk inclusion criterion. In the present
review, among the 5 trials included in the low risk-group,
4 studied healthy nulliparous women,11,12,14,15 and 1 included
44% nulliparous women.13
Considerations of cost and effects of preeclampsia pre-
vention are justified by its high prevalence and by the as-
sociated high maternal and perinatal morbidity/mortality
rates.34 Primary prevention, consisting of averting the oc-
currence of the disease, requires an understanding of its
etiology. As the fundamental problem of misalliance be-
tween trophoblast and maternal tissue is not well under-
stood, true etiological intervention has not been possible
in preeclampsia. On the other hand, secondary prevention,
consisting of at least slowing down the disease process be-
fore it becomes clinically apparent, is based on pathophysi-
ological concepts. Low-dose aspirin has been used as a
strategy for secondary prevention of preeclampsia.34 How-
ever, as observed in recent studies and in the present analy-
sis, low-dose aspirin exhibits nothing but a small effect in
the prevention of preeclampsia, and this benefice is
restrcited to the high-risk group, showing that we still need
to study and better understand the pathophysiology of the
preeclampsia.
Causes of conflicting results may not be explained by
the timing of aspirin administration and its dosage, but
more probably by differences in the inclusion criteria. Ad-
ditionally, methods of prediction of preeclampsia seem to
have questionable results. Recently, many severe cases of
preeclampsia have been associated with thrombophilia and
antiphospholipid syndromes,44-52 situations in which low-
dose of aspirin seems to have beneficial effects. As these
diseases were not routinely screened for, many trials in-
cluded these women, without realizing the fact, which may
explain some of the good results with low-dose aspirin in
the prevention of preeclampsia in earlier studies.
Therefore, in further randomized controlled trials evalu-
ating the use of low-dose aspirin, participants should be di-
vided into groups according to parity, risk for preeclampsia,
and the presence of any prothrombotic factor or disease.
Because secondary prevention is based on pathophysiology,
we believe our analysis shows that pathophysiological proc-
ess involved in preeclampsia still require further study.
RESUMO
Ruano R, Fontes RS, Zugaib M. Revisando a prevenção
da pré-eclâmpsia com aspirina em baixa dose – uma revisão
sistemática dos principais estudos randomizados
controlados. Clinics. 2005;60(5):407-14.
Esta revisão busca reúne estudos sobre a eficácia da aspirina
em baixas doses na prevenção da pré-eclâmpsia em
pacientes de alto e baixo risco. Identificamos estudos
clínicos randomizados controlados usando baixas doses de
aspirina para prevenir a pré-eclâmpsia, publicados no
MEDLINE. Vinte e dois estudos preencheram nossos
critérios de inclusão. Dividimos os estudos de acordo com
a população estudada em dois grupos: estudos com
mulheres de baixo risco para pré-eclâmpsia e estudos com
pacientes de alto risco. A principal medida de efeito foi a
incidência de pré-eclâmpsia em pacientes que usaram pla-
cebo ou aspirina, na qual os riscos relativos e os intervalos
de confiança de 95% foram calculados para os grupos de
pacientes de baixo e de alto risco para pré-eclâmpsia. Um
total de 33.598 pacientes foram estudadas, dentre as quais
cinco estudos com 16.700 pacientes de baixo risco e 17
estudos incluindo 16.898 pacientes de alto risco. As
incidências de pré-eclâmpsia no geral, no grupo de baixo
e no de alto risco foram de 6,40% (2.150/33.598), 3,75%
(626/17.700), e 9,01% (1.524/16.898), respectivamente.
Baixas doses de aspirina não tiveram efeito estatístico
significante na redução da incidência de pré-eclâmpsia em
pacientes de baixo risco (RR=0.95, 95%CI = 0.81-1.11),
porém apresentaram pequenos benefícios em mulheres de
alto risco (RR=0.87, 95%CI=0.79-0.96). Esta análise leva
à conclusão de que baixas doses de aspirina têm pequeno
efeito na redução da incidência da pré-eclâmpsia em
pacientes com alto risco de desenvolver a doença.
UNITERMOS: Pré-eclâmpsia. Prevenção. Aspirina.
Metanálise.
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